Evidence map›Paper›PMID 40200355›Full record

ArticleBMC pulmonary medicine2025

Cost effectiveness of a novel swallowing and respiratory sensation assessment and a modelled intervention to reduce acute exacerbations of COPD.

Isabella Epiu, Christine R Jenkins, Norma B Bulamu, Andreas Kuznik

Abstract read
In one paragraph

Article in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Isabella EpiuPrince of Wales clinical School, The University of New South Wales, Sydney, NSW, 2052, Australia. iepiu@kab.ac.ug.ORCID http://orcid.org/0000-0001-9003-3188
Christine R JenkinsPrince of Wales clinical School, The University of New South Wales, Sydney, NSW, 2052, Australia.
Norma B BulamuCollege of Medicine and Public Health Flinders Health and Medical Research Institute, Flinders University, Adelaide, SA, Australia.ORCID http://orcid.org/0000-0003-4822-4858
Andreas KuznikHealth Economics and Outcomes Research, Regeneron Pharmaceuticals, Tarrytown, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Swallowing impairment observed in ~ 20% of people with Chronic Obstructive Pulmonary Disease (COPD) may increase the risk of aspiration pneumonia and acute exacerbations. We designed a decision analytic model to assess the cost-effectiveness of the Swallowing and Respiratory Sensation Assessment (SwaRSA) tests and swallowing rehabilitation to reduce COPD exacerbations. We believe that swallowing rehabilitation to improve coordination of swallowing and breathing may reduce exacerbations in people with COPD.From the Australia health system perspective, we assessed the cost effectiveness of four tests relative to standard of care, or no testing, over a time horizon of one year. The SwaRSA tests assessed relative to a standard of care arm of no testing: included the Eating Assessment Tool (EAT-10) score, Swallowing Capacity of Liquids, Tongue Strength Assessment, and Respiratory Sensation Assessment, in people with moderate to severe COPD. Outcome measures were COPD exacerbations per year, which were converted into quality adjusted life years (QALYs). Model inputs including costs, test sensitivities and specificities, COPD exacerbation risks, and exacerbation-related utilities were derived from published sources. Our assumptions on the costs, recovery, and risk reduction are based on the available data on pulmonary rehabilitation in COPD.Relative to no-SwaRSA, three individual testing strategies were found to be cost-effective at incremental cost effectiveness ratio per QALY ranging from $27,000 to $37,000 AUD assuming a willingness to pay of $50,000 AUD. The EAT-10 and the tongue strength were the two dominant options on the cost-effectiveness frontier. Model results were robust to variations in one-way and probabilistic sensitivity analyses.In COPD, SwaRSA modelling suggests that self-assessment with the EAT-10 and subsequent intervention is highly cost-effective relative to no-SwaRSA.

Indexed as

DeglutitionDeglutition DisordersPulmonary Disease, Chronic ObstructiveAgedAustraliaCost-Benefit AnalysisCost-Effectiveness AnalysisDisease ProgressionFemaleHumansMalePneumonia, AspirationQuality-Adjusted Life YearsAirway sensationChronic respiratory diseasesCost effectiveness analysisDysphagiaSwallowingSwaRSA

Identifiers

PMID40200355
PMCPMC11980303

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.